These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20940397)

  • 21. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
    Kline J; Brown IE; Zha YY; Blank C; Strickler J; Wouters H; Zhang L; Gajewski TF
    Clin Cancer Res; 2008 May; 14(10):3156-67. PubMed ID: 18483384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long peptide vaccination can lead to lethality through CD4+ T cell-mediated cytokine storm.
    Kitamura H; Sedlik C; Jacquet A; Zaragoza B; Dusseaux M; Premel V; Sastre-Garau X; Lantz O
    J Immunol; 2010 Jul; 185(2):892-901. PubMed ID: 20543102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
    Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.
    Wang LX; Li R; Yang G; Lim M; O'Hara A; Chu Y; Fox BA; Restifo NP; Urba WJ; Hu HM
    Cancer Res; 2005 Nov; 65(22):10569-77. PubMed ID: 16288050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemically administered gp100 encoding DNA vaccine for melanoma using water-in-oil-in-water multiple emulsion delivery systems.
    Kalariya M; Amiji MM
    Int J Pharm; 2013 Sep; 453(2):400-7. PubMed ID: 23702000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity.
    Neal ZC; Bates MK; Albertini MR; Herweijer H
    Mol Ther; 2007 Feb; 15(2):422-30. PubMed ID: 17235322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.
    Ji Y; Wrzesinski C; Yu Z; Hu J; Gautam S; Hawk NV; Telford WG; Palmer DC; Franco Z; Sukumar M; Roychoudhuri R; Clever D; Klebanoff CA; Surh CD; Waldmann TA; Restifo NP; Gattinoni L
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):476-81. PubMed ID: 25548153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
    Palmer DC; Balasubramaniam S; Hanada K; Wrzesinski C; Yu Z; Farid S; Theoret MR; Hwang LN; Klebanoff CA; Gattinoni L; Goldstein AL; Yang JC; Restifo NP
    J Immunol; 2004 Dec; 173(12):7209-16. PubMed ID: 15585842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
    Villarreal DO; Chin D; Smith MA; Luistro LL; Snyder LA
    Oncotarget; 2017 Jun; 8(24):39117-39130. PubMed ID: 28388572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
    Lou Y; Wang G; Lizée G; Kim GJ; Finkelstein SE; Feng C; Restifo NP; Hwu P
    Cancer Res; 2004 Sep; 64(18):6783-90. PubMed ID: 15374997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.
    Molino NM; Neek M; Tucker JA; Nelson EL; Wang SW
    Biomaterials; 2016 Apr; 86():83-91. PubMed ID: 26894870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.
    Slaney CY; von Scheidt B; Davenport AJ; Beavis PA; Westwood JA; Mardiana S; Tscharke DC; Ellis S; Prince HM; Trapani JA; Johnstone RW; Smyth MJ; Teng MW; Ali A; Yu Z; Rosenberg SA; Restifo NP; Neeson P; Darcy PK; Kershaw MH
    Clin Cancer Res; 2017 May; 23(10):2478-2490. PubMed ID: 27965307
    [No Abstract]   [Full Text] [Related]  

  • 35. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
    Overwijk WW; Theoret MR; Finkelstein SE; Surman DR; de Jong LA; Vyth-Dreese FA; Dellemijn TA; Antony PA; Spiess PJ; Palmer DC; Heimann DM; Klebanoff CA; Yu Z; Hwang LN; Feigenbaum L; Kruisbeek AM; Rosenberg SA; Restifo NP
    J Exp Med; 2003 Aug; 198(4):569-80. PubMed ID: 12925674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
    Wrzesinski C; Paulos CM; Gattinoni L; Palmer DC; Kaiser A; Yu Z; Rosenberg SA; Restifo NP
    J Clin Invest; 2007 Feb; 117(2):492-501. PubMed ID: 17273561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).
    Salem ML; Díaz-Montero CM; Al-Khami AA; El-Naggar SA; Naga O; Montero AJ; Khafagy A; Cole DJ
    J Immunol; 2009 Feb; 182(4):2030-40. PubMed ID: 19201856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy.
    Cho HI; Reyes-Vargas E; Delgado JC; Celis E
    Cancer Res; 2012 Apr; 72(8):1986-95. PubMed ID: 22367213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.
    Kadayakkara DK; Korrer MJ; Bulte JW; Levitsky HI
    Cancer Res; 2015 Jan; 75(1):51-61. PubMed ID: 25388285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploiting the mutanome for tumor vaccination.
    Castle JC; Kreiter S; Diekmann J; Löwer M; van de Roemer N; de Graaf J; Selmi A; Diken M; Boegel S; Paret C; Koslowski M; Kuhn AN; Britten CM; Huber C; Türeci O; Sahin U
    Cancer Res; 2012 Mar; 72(5):1081-91. PubMed ID: 22237626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.